ResearcherFirst Affiliated Hospital of Bengbu Medical CollegeActive in the last 2 years

Xiao Wu

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-9156-5052; OpenAlex author ID A5109153404. Sources: OpenAlex.

Their work

Papers: 2
Trials: 0
Grants: 0
Labs led: 0
Collaborators: 4

Papers, trials and grants by year

2020: 1 paper · 2021: none · 2022: none · 2023: none · 2024: none · 2025: 1 paper

Papers 2

CCL19 Suppresses Pancreatic Cancer Progression via Immune Microenvironment Remodeling: Bioinformatics and Functional Insights Co-author DOI 10.21203/rs.3.rs-7426239/v1 ↗
SRPX2 boosts pancreatic cancer chemoresistance by activating PI3K/AKT axis. Co-author DOI 10.1515/med-2020-0157 ↗

Closest collaborators

The 4 strongest of 4 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

Yongxia Chen · 1 shared paper, 2025 · strength 0.27
- Paper CCL19 Suppresses Pancreatic Cancer Progression via Immune Microenvironment Remodeling: Bioinformatics and Functional In… DOI 10.21203/rs.3.rs-7426239/v1 ↗
Fang Su · 1 shared paper, 2025 · strength 0.27
- Paper CCL19 Suppresses Pancreatic Cancer Progression via Immune Microenvironment Remodeling: Bioinformatics and Functional In… DOI 10.21203/rs.3.rs-7426239/v1 ↗
Yimei Ou · 1 shared paper, 2020 · strength 0.15
- Paper SRPX2 boosts pancreatic cancer chemoresistance by activating PI3K/AKT axis. DOI 10.1515/med-2020-0157 ↗
Zhenyuan Gao · 1 shared paper, 2020 · strength 0.15
- Paper SRPX2 boosts pancreatic cancer chemoresistance by activating PI3K/AKT axis. DOI 10.1515/med-2020-0157 ↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.